New Pilot EQA Scheme – Rare Neurological Diseases (RND)
EMQN and ERN-RND are collaborating to provide a new pilot RND EQA. Samples for this pilot will be distributed Autumn 2021 and will be suitable for laboratories running a rare neurological disease panel, clinical exome or WGS.
Please contact office@EMQN.org quoting your EMQN participant number and 'RND pilot EQA' in the subject line to participate. Closing date for applications is 18th July 2021. Places will be offered on a first-come-first-served basis. Costs of participation will be £305.
EQAs for SARS-Cov-2 and other respiratory viruses open for registration
We have EQAs for SARS-Cov-2 only, or in conjunction with other major respiratory viruses (RSV, Influenza) available for registration. Use the button below to browse our scheme catalogue.
We are a not-for-profit organisation promoting quality in genetic testing by establishing, harmonising and disseminating best practice.
We provide ISO 17043 accredited External Quality Assessment (EQA) or Proficiency Testing (PT) schemes which are designed to test the whole analytical process of a molecular diagnostics laboratory including the ability to interpret data in the light of clinical information supplied with a referral, and to produce a clear and accurate report.
The latest news and press releases
Live webinar: Standardisation in Tumor Mutation Burden (TMB) assessment - click link for more details- https://t.co/fpqKqyJsiz
FINAL results from 2020 BRCA Ovarian EQA schemes published today - please log in to your EMQN account to access the… https://t.co/LJDOV6sweQ
FINAL results from 2020 Lung Cancer (plasma testing) EQA scheme were published today. Please login to your EMQN ac… https://t.co/0wvF2oVa65
Validated genotypes published today for 2021 Germline EQA schemes - https://t.co/kezRu0jz1s
Invitation to a live webinar: lessons learned from the 2020 ovarian and prostate cancer EQA schemes - click here to… https://t.co/U72Bgpo0xE